EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate

Mitsuhisa Nishimoto iD, Marco A De Velasco iD, Yutaka Yamamoto iD, Saizo Fujimoto iD, Yasunori Akashi iD, Shingo Toyoda iD, Mamoru Hashimoto iD, Shogo Adomi iD, Eri Banno iD, Yoshitaka Saito iD, Takafumi Minami iD, Akihide Hirayama iD und 3 weitere

The Prostate · 2025

DOI: 10.1002/pros.24865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Mitsuhisa Nishimoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan. Hauptthemen laut MEDLINE: Receptors, Androgen, Abiraterone Acetate, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of abiraterone acetate varies among patients with high‐risk metastatic castration‐sensitive prostate cancer (mCSPC). Both androgen receptor (AR) and cytokeratin 18 (CK18) are markers of the luminal lineage of prostate cancer, and their expression levels have been suggested to affect the response to androgen deprivation therapy (ADT). This study aimed to predict the efficacy of abiraterone acetate in high‐risk mCSPC via immunohistochemical staining of biopsy specimens obtained at the time of prostate cancer diagnosis.

Methods

We retrospectively analyzed 44 patients treated with abiraterone acetate in combination with ADT. AR and CK18 expression in prostate biopsy specimens were assessed using immunohistochemical staining.

Results

AR and CK18 staining was not significantly associated with overall survival (OS). However, low AR staining was significantly associated with a shorter time to castration‐resistant prostate cancer (TTCRPC) compared with high AR staining (log‐rank test, p = 0.018). Similarly, low CK18 staining was significantly associated with a shorter TTCRPC compared with high CK18 staining (log‐rank test, p = 0.037).

Conclusions

Immunohistochemical analysis of AR or CK18 expression in biopsy specimens may serve as a predictive biomarker of high‐risk mCSPC treated with abiraterone acetate. Trial Registration: None

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenAbiraterone AcetateProstatic Neoplasms, Castration-ResistantHumansMaleRetrospective StudiesAgedPrognosisMiddle AgedImmunohistochemistryAged, 80 and overAndrogen AntagonistsBiomarkers, Tumor

Stichwörter der Autor:innen

abiraterone acetateandrogen receptormetastatic castration‐sensitive prostate carcinoma

Substanzen

Receptors, AndrogenAbiraterone AcetateAR protein, humanAndrogen AntagonistsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Department of Urology, Kindai University Nara Hospital, Ikoma, Japan.

ORCID-Profile: Mitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, Saizo Fujimoto, Yasunori Akashi, Shingo Toyoda, Mamoru Hashimoto, Shogo Adomi, Eri Banno, Yoshitaka Saito, Takafumi Minami, Akihide Hirayama, Kazuhiro Yoshimura, Hirotsugu Uemura, Kazutoshi Fujita

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Nishimoto, M., De Velasco, M. A., Yamamoto, Y., Fujimoto, S., Akashi, Y., Toyoda, S., Hashimoto, M., Adomi, S., Banno, E., Saito, Y., Minami, T., Hirayama, A., Yoshimura, K., Uemura, H., & Fujita, K. (2025). Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. The Prostate. https://doi.org/10.1002/pros.24865

Vancouver

Nishimoto M, De Velasco MA, Yamamoto Y, Fujimoto S, Akashi Y, Toyoda S, et al. Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. The Prostate. 2025. doi:10.1002/pros.24865

BibTeX
@article{Nishimoto2025,
  author = {Nishimoto, Mitsuhisa and De Velasco, Marco A and Yamamoto, Yutaka and Fujimoto, Saizo and Akashi, Yasunori and Toyoda, Shingo and Hashimoto, Mamoru and Adomi, Shogo and Banno, Eri and Saito, Yoshitaka and Minami, Takafumi and Hirayama, Akihide and Yoshimura, Kazuhiro and Uemura, Hirotsugu and Fujita, Kazutoshi},
  title = {Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24865}
}
Kostenlos starten →